Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.96
VIVO's Cash-to-Debt is ranked lower than
68% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. VIVO: 0.96 )
Ranked among companies with meaningful Cash-to-Debt only.
VIVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 5.02 Max: No Debt
Current: 0.96
Equity-to-Asset 0.68
VIVO's Equity-to-Asset is ranked higher than
62% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. VIVO: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
VIVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.76 Max: 0.92
Current: 0.68
0.35
0.92
Interest Coverage 27.84
VIVO's Interest Coverage is ranked lower than
57% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. VIVO: 27.84 )
Ranked among companies with meaningful Interest Coverage only.
VIVO' s Interest Coverage Range Over the Past 10 Years
Min: 27.84  Med: No Debt Max: No Debt
Current: 27.84
Piotroski F-Score: 5
Altman Z-Score: 6.47
Beneish M-Score: -2.96
WACC vs ROIC
5.93%
17.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 23.62
VIVO's Operating Margin % is ranked higher than
92% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. VIVO: 23.62 )
Ranked among companies with meaningful Operating Margin % only.
VIVO' s Operating Margin % Range Over the Past 10 Years
Min: 23.62  Med: 28.66 Max: 32.9
Current: 23.62
23.62
32.9
Net Margin % 15.02
VIVO's Net Margin % is ranked higher than
90% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. VIVO: 15.02 )
Ranked among companies with meaningful Net Margin % only.
VIVO' s Net Margin % Range Over the Past 10 Years
Min: 15.02  Med: 18.98 Max: 22.09
Current: 15.02
15.02
22.09
ROE % 17.72
VIVO's ROE % is ranked higher than
82% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. VIVO: 17.72 )
Ranked among companies with meaningful ROE % only.
VIVO' s ROE % Range Over the Past 10 Years
Min: 17.72  Med: 22.86 Max: 25.78
Current: 17.72
17.72
25.78
ROA % 11.77
VIVO's ROA % is ranked higher than
89% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. VIVO: 11.77 )
Ranked among companies with meaningful ROA % only.
VIVO' s ROA % Range Over the Past 10 Years
Min: 11.77  Med: 20.4 Max: 22.5
Current: 11.77
11.77
22.5
ROC (Joel Greenblatt) % 52.31
VIVO's ROC (Joel Greenblatt) % is ranked higher than
82% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. VIVO: 52.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VIVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 52.31  Med: 67.18 Max: 89.27
Current: 52.31
52.31
89.27
3-Year Revenue Growth Rate 0.90
VIVO's 3-Year Revenue Growth Rate is ranked lower than
62% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. VIVO: 0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VIVO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 10.4 Max: 25
Current: 0.9
0.9
25
3-Year EBITDA Growth Rate -3.00
VIVO's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. VIVO: -3.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VIVO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3  Med: 15.7 Max: 67.4
Current: -3
-3
67.4
3-Year EPS without NRI Growth Rate -5.80
VIVO's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. VIVO: -5.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VIVO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 20.3 Max: 64.6
Current: -5.8
-27.1
64.6
GuruFocus has detected 2 Warning Signs with Meridian Bioscience Inc $VIVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VIVO's 30-Y Financials

Financials (Next Earnings Date: 2017-07-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

VIVO Guru Trades in Q2 2016

Joel Greenblatt 264,250 sh (+54.37%)
Paul Tudor Jones 40,961 sh (+3.24%)
Jim Simons 1,761,076 sh (+2.95%)
Mario Gabelli 140,000 sh (unchged)
Chuck Royce 48,300 sh (unchged)
Keeley Asset Management Corp 82,375 sh (-7.73%)
» More
Q3 2016

VIVO Guru Trades in Q3 2016

Jim Simons 1,914,676 sh (+8.72%)
Chuck Royce 48,300 sh (unchged)
Mario Gabelli 140,000 sh (unchged)
Keeley Asset Management Corp 82,375 sh (unchged)
Joel Greenblatt 246,898 sh (-6.57%)
Paul Tudor Jones 27,903 sh (-31.88%)
» More
Q4 2016

VIVO Guru Trades in Q4 2016

Discovery Group I, LLC 340,282 sh (New)
Chuck Royce 116,928 sh (+142.09%)
Mario Gabelli 140,000 sh (unchged)
Keeley Asset Management Corp Sold Out
Jim Simons 1,873,200 sh (-2.17%)
Joel Greenblatt 211,281 sh (-14.43%)
Paul Tudor Jones 21,515 sh (-22.89%)
» More
Q1 2017

VIVO Guru Trades in Q1 2017

Barrow, Hanley, Mewhinney & Strauss 7,605 sh (New)
Paul Tudor Jones 49,868 sh (+131.78%)
Chuck Royce 157,894 sh (+35.04%)
Mario Gabelli 175,000 sh (+25.00%)
Joel Greenblatt 234,281 sh (+10.89%)
Jim Simons 1,988,276 sh (+6.14%)
Discovery Group I, LLC Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:NEO, NAS:LNTH, NYSE:ARA, NAS:NTRA, NAS:NRCIA, NAS:HSKA, NYSE:ENZ, NAS:NVDQ, NYSE:NVTA, NAS:PACB, NAS:RDNT, NAS:QDEL, NAS:BEAT, NAS:OXFD, NAS:SRDX, NAS:ONVO, NAS:QTNT, NAS:ALOG, NAS:MGEN, OTCPK:EPGNF » details
Traded in other countries:MR4.Germany,
Headquarter Location:USA
Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases.

Meridian Bioscience Inc was incorporated in Ohio in 1976. The Company is an integrated life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals under cGMP conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Its segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries comprising North, Central and South America (the Americas); Europe, Middle East and Africa (EMEA); and other countries outside of the Americas and EMEA (rest of the world, or ROW). In the Diagnostics Segment, its testing platforms include: Isothermal DNA Amplification (illumigene brand); Rapid Immunoassay (TRU, ImmunoCard and ImmunoCard STAT! brands); and Enzyme-linked Immunoassay ( Premier brand). Its product portfolio includes over 140 diagnostic tests and transport media, and is marketed to acute care hospitals, reference laboratories and outpatient clinics in over 70 countries around the world. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Top Ranked Articles about Meridian Bioscience Inc

Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women
Meridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of Antigens and Antibodies for Diagnostic Applications
Meridian Bioscience Inc. (Nasdaq: VIVO) to Ring The Nasdaq Stock Market Opening Bell
New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria
ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection
Bioline Launches New JetSeq DNA Quantification Kits
CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio for Next Generation Sequencing (NGS) sample preparation.
The new JetSeq™ Library Quantification Kit is a qPCR-based assay that provides fast, accurate and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina compatible NGS libraries. The JetSeq™ Library Quantification Kit relies on SYBR®1 Green I for detection and contains all of the components required for library quantification, including dilution buffer, P5 and P7 adapter primers and six pre-diluted DNA standards to minimize pipetting, reduce variability and thereby increase reproducibility. The kit has sufficient standards to quantify eighteen libraries on individual plates or up to seventy-six libraries when multiple libraries are quantified on the same plate.Marco Calzavara, President of Bioline commented, “The release of the new JetSeq™ Library Quantification Kit compliments the JetSeq™ Library preparation kits that Bioline launched last month, moving us even further into the NGS space. The kit builds on our extensive knowledge in qPCR, providing a fast, sensitive and reliable solution to determine library concentrations, giving customers confidence in the cluster density loaded on Illumina sequencing platforms.”Richard L. Eberly, President, Chief Commercial Officer, stated, “We are pleased to announce the release of the new JetSeq™ Library Quantification Kit; this is an important addition to our ever-increasing portfolio of NGS products and gives our life science customers greater confidence in the quantification of their sequencing libraries. The further development of the JetSeq™ family shows our commitment, not just to the continued development and expansion of products from Bioline, but also to our customers, giving them a greater support around this fast-growing market.”About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.FOR ADDITIONAL INFORMATION:
For more information about Bioline, please visit http://www.bioline.com.1 SYBR is a registered trademark of Thermo Fisher Scientific.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
[email protected]

Read more...
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa

CINCINNATI, March 07, 2017 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) announced today that Magellan Diagnostics Inc., a business unit of Meridian since March 2016, has signed an exclusive distribution agreement with Biofirm Technologies, one of the leading providers of laboratory equipment, consumables, reagents, and medical equipment in East and Central Africa. Magellan Diagnostics’ LeadCare® II blood lead testing system is the only FDA cleared, rapid and portable system capable of providing a quantitative blood lead result in just three minutes.  LeadCare II is used in thousands of pediatric and primary care settings in the United States to help doctors diagnose lead exposure quickly and easily, from just two drops of blood. 
Lead exposure is a global health threat because, even at low levels, it can cause behavioral and learning disabilities, hyperactivity and lower IQ, as well as hypertension and kidney dysfunction. A 2015 report by the World Health Organization on lead poisoning explains that African countries have a “range of ongoing, lead-related public health concerns” driven by numerous “sources of lead to which African children may be exposed, often simultaneously.”  These sources include: lead paint in homes, on toys and on playground equipment; occupational sources from mining, smelting, battery manufacture/recycling, and e-waste processing; as well traditional medicines, cosmetics, and artisanal cookware. The report goes on to describe a health economic study that “conservatively estimated that, annually, around 98.2 million IQ points are lost in Africa due to lead exposure, translating into economic losses of US $134.7 billion.” Describing the need for LeadCare II in Africa, Amy Winslow, president and CEO of Magellan Diagnostics explained, “We have seen devastating news of entire communities destroyed by lead poisoning, whether by artisanal gold mining in Zamfara, Nigeria, or from industrial exposures in Mombasa, Kenya.  Sadly, behind these headlines is the quieter reality that lead exposure sources are myriad, resulting in blood lead levels for children and pregnant women that are far above what we see in the U.S. To understand the challenges of lead poisoning, and to find solutions, you must have a simple way to identify who is most at risk.  We look forward to helping Biofirm Technologies provide LeadCare II to address this need.” Lourdes Weltzien, president of Meridian Asia Pacific, who is in charge of leveraging Meridian’s global footprint to expand distribution of LeadCare II commented, “We have seen incredible interest in LeadCare II from regions across the globe, especially in areas like Africa, China, India and Australia where battery manufacturing/recycling, e-waste, or mining and smelting industries are common. Lead poisoning is a devastating and preventable disease. We are looking forward to having a positive impact with a device that can be used anywhere and provide answers in 3 minutes, ultimately helping to preserve the potential of millions of children.” Distribution activities with Biofirm Technologies will begin immediately, focusing on developing awareness, at clinical and governmental levels, about the problem of lead poisoning. Education will address sources of lead exposure, consequences – including deficits in fertility, fetal growth, intellectual development, learning and behavior – as well as how portable testing can rapidly identify at-risk populations. About Magellan Diagnostics, Inc.  
Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. A business unit of Meridian Bioscience, Inc., Magellan is headquartered outside Boston in Billerica, Massachusetts, and is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure.  We are committed to educating clinicians, policy makers, payers, families and communities about the permanent health damage caused by lead and how to detect and address lead exposure.  For more information, visit www.magellandx.com. About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Contact:
Amy Winslow
President, Chief Executive Officer
Magellan Diagnostics
Phone: 978-856-2345
Email:[email protected]

Lourdes Weltzien
President of Meridian Asia Pacific
Telephone: 901-382-8716 or
Email: [email protected]

John A. Kraeutler
Chairman, Chief Executive Officer
Meridian Bioscience, Inc.
Phone:  513.271.3700
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 19.64
VIVO's PE Ratio is ranked higher than
72% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. VIVO: 19.64 )
Ranked among companies with meaningful PE Ratio only.
VIVO' s PE Ratio Range Over the Past 10 Years
Min: 18.07  Med: 25.97 Max: 48.49
Current: 19.64
18.07
48.49
Forward PE Ratio 18.45
VIVO's Forward PE Ratio is ranked higher than
64% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. VIVO: 18.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.64
VIVO's PE Ratio without NRI is ranked higher than
73% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. VIVO: 19.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
VIVO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 18.07  Med: 25.97 Max: 48.28
Current: 19.64
18.07
48.28
Price-to-Owner-Earnings 16.10
VIVO's Price-to-Owner-Earnings is ranked higher than
73% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. VIVO: 16.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VIVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.86  Med: 30.78 Max: 68.13
Current: 16.1
14.86
68.13
PB Ratio 3.47
VIVO's PB Ratio is ranked higher than
54% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. VIVO: 3.47 )
Ranked among companies with meaningful PB Ratio only.
VIVO' s PB Ratio Range Over the Past 10 Years
Min: 3.19  Med: 5.93 Max: 11.73
Current: 3.47
3.19
11.73
PS Ratio 3.01
VIVO's PS Ratio is ranked higher than
56% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. VIVO: 3.01 )
Ranked among companies with meaningful PS Ratio only.
VIVO' s PS Ratio Range Over the Past 10 Years
Min: 2.74  Med: 5.14 Max: 10.96
Current: 3.01
2.74
10.96
Price-to-Free-Cash-Flow 15.17
VIVO's Price-to-Free-Cash-Flow is ranked higher than
69% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. VIVO: 15.17 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VIVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.01  Med: 29.61 Max: 70.85
Current: 15.17
14.01
70.85
Price-to-Operating-Cash-Flow 13.53
VIVO's Price-to-Operating-Cash-Flow is ranked higher than
59% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. VIVO: 13.53 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VIVO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.5  Med: 24.55 Max: 49.75
Current: 13.53
12.5
49.75
EV-to-EBIT 12.37
VIVO's EV-to-EBIT is ranked higher than
88% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. VIVO: 12.37 )
Ranked among companies with meaningful EV-to-EBIT only.
VIVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 16.6 Max: 35.7
Current: 12.37
11.4
35.7
EV-to-EBITDA 10.56
VIVO's EV-to-EBITDA is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. VIVO: 10.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
VIVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.9  Med: 15 Max: 31.9
Current: 10.56
9.9
31.9
PEG Ratio 5.05
VIVO's PEG Ratio is ranked lower than
77% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. VIVO: 5.05 )
Ranked among companies with meaningful PEG Ratio only.
VIVO' s PEG Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.55 Max: 25.43
Current: 5.05
0.98
25.43
Shiller PE Ratio 16.72
VIVO's Shiller PE Ratio is ranked higher than
87% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. VIVO: 16.72 )
Ranked among companies with meaningful Shiller PE Ratio only.
VIVO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.24  Med: 35.62 Max: 134.75
Current: 16.72
15.24
134.75
Current Ratio 6.47
VIVO's Current Ratio is ranked higher than
82% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. VIVO: 6.47 )
Ranked among companies with meaningful Current Ratio only.
VIVO' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 5.42 Max: 11.4
Current: 6.47
1.4
11.4
Quick Ratio 4.34
VIVO's Quick Ratio is ranked higher than
72% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. VIVO: 4.34 )
Ranked among companies with meaningful Quick Ratio only.
VIVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.79 Max: 9.6
Current: 4.34
0.87
9.6
Days Inventory 217.53
VIVO's Days Inventory is ranked lower than
89% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. VIVO: 217.53 )
Ranked among companies with meaningful Days Inventory only.
VIVO' s Days Inventory Range Over the Past 10 Years
Min: 130.86  Med: 178.85 Max: 217.53
Current: 217.53
130.86
217.53
Days Sales Outstanding 49.59
VIVO's Days Sales Outstanding is ranked higher than
74% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. VIVO: 49.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
VIVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.91  Med: 53.72 Max: 67.24
Current: 49.59
44.91
67.24
Days Payable 32.09
VIVO's Days Payable is ranked lower than
62% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. VIVO: 32.09 )
Ranked among companies with meaningful Days Payable only.
VIVO' s Days Payable Range Over the Past 10 Years
Min: 25.32  Med: 33.24 Max: 45.39
Current: 32.09
25.32
45.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.66
VIVO's Dividend Yield % is ranked higher than
92% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. VIVO: 4.66 )
Ranked among companies with meaningful Dividend Yield % only.
VIVO' s Dividend Yield % Range Over the Past 10 Years
Min: 1.24  Med: 3.52 Max: 6.32
Current: 4.66
1.24
6.32
Dividend Payout Ratio 1.02
VIVO's Dividend Payout Ratio is ranked lower than
90% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. VIVO: 1.02 )
Ranked among companies with meaningful Dividend Payout Ratio only.
VIVO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.95 Max: 1.17
Current: 1.02
0.61
1.17
3-Year Dividend Growth Rate 1.70
VIVO's 3-Year Dividend Growth Rate is ranked lower than
76% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.60 vs. VIVO: 1.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
VIVO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14 Max: 69.4
Current: 1.7
0
69.4
Forward Dividend Yield % 3.61
VIVO's Forward Dividend Yield % is ranked higher than
87% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. VIVO: 3.61 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.97
VIVO's 5-Year Yield-on-Cost % is ranked higher than
91% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. VIVO: 4.97 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
VIVO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.32  Med: 3.75 Max: 6.74
Current: 4.97
1.32
6.74
3-Year Average Share Buyback Ratio -0.50
VIVO's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. VIVO: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VIVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.3  Med: -0.7 Max: 0
Current: -0.5
-6.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 12.35
VIVO's Price-to-Net-Current-Asset-Value is ranked lower than
66% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. VIVO: 12.35 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VIVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.65  Med: 11.48 Max: 65
Current: 12.35
2.65
65
Price-to-Tangible-Book 7.23
VIVO's Price-to-Tangible-Book is ranked lower than
65% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. VIVO: 7.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VIVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.73  Med: 8.64 Max: 24.67
Current: 7.23
1.73
24.67
Price-to-Intrinsic-Value-Projected-FCF 1.25
VIVO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. VIVO: 1.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VIVO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.54  Med: 2.6 Max: 5.98
Current: 1.25
0.54
5.98
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.84
VIVO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
53% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. VIVO: 1.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.58
VIVO's Price-to-Median-PS-Value is ranked higher than
82% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. VIVO: 0.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VIVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.78 Max: 2.01
Current: 0.58
0.12
2.01
Price-to-Graham-Number 2.51
VIVO's Price-to-Graham-Number is ranked higher than
61% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. VIVO: 2.51 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VIVO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.23  Med: 3.33 Max: 6.32
Current: 2.51
1.23
6.32
Earnings Yield (Greenblatt) % 8.07
VIVO's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. VIVO: 8.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VIVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 6 Max: 8.8
Current: 8.07
2.8
8.8
Forward Rate of Return (Yacktman) % 7.31
VIVO's Forward Rate of Return (Yacktman) % is ranked lower than
51% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. VIVO: 7.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
VIVO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.7  Med: 10.5 Max: 26.8
Current: 7.31
1.7
26.8

More Statistics

Revenue (TTM) (Mil) $198.6
EPS (TTM) $ 0.71
Beta0.65
Short Percentage of Float11.54%
52-Week Range $10.75 - 20.68
Shares Outstanding (Mil)42.20

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 197 200
EPS ($) 0.75 0.72
EPS without NRI ($) 0.75 0.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VIVO

Headlines

Articles On GuruFocus.com
Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to May 10 2017 
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiativ May 09 2017 
Meridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of May 04 2017 
Meridian Bioscience Inc. (Nasdaq: VIVO) to Ring The Nasdaq Stock Market Opening Bell Apr 26 2017 
New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria Apr 24 2017 
ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection Apr 17 2017 
Bioline Launches New JetSeq DNA Quantification Kits Mar 27 2017 
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs E Mar 07 2017 
9 Cheap High-Yield Stocks Feb 23 2017 
The Four Horsemen: Risk, Uncertainty, Price and Value Mar 19 2015 

More From Other Websites
Top Ranked Income Stocks to Buy for May 24th May 24 2017
Robbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO)... May 22 2017
ETFs with exposure to Meridian Bioscience, Inc. : May 19, 2017 May 19 2017
UPDATE 3-U.S. health officials warn of problems with Meridian lead tests May 18 2017
Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2017 By the Numbers : May 18, 2017 May 18 2017
Meridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : May 18,... May 18 2017
Tests for lead poisoning may be faulty, US regulators warn May 17 2017
Meridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics May 17 2017
​FDA says Billerica firm’s lead tests may be faulty in some cases May 17 2017
Meridian Bioscience stock plummets after FDA warns subsidiary's lead tests may be inaccurate May 17 2017
One of Cincinnati's largest public companies launches CEO search May 10 2017
Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to... May 10 2017
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education... May 09 2017
Meridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of... May 04 2017
Meridian Bioscience beats 2Q profit forecasts Apr 27 2017
Today's Bell Ringer, April 27, 2017 Apr 27 2017
Meridian Bioscience Reports Second Quarter 2017 Operating Results, Declares Regular Cash Dividend,... Apr 27 2017
Meridian Bioscience Inc. (Nasdaq: VIVO) to Ring The Nasdaq Stock Market Opening Bell Apr 26 2017
New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria Apr 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)